Moa Technology raises £22.2m Series C funding round

Parkwalk is pleased to announce its latest investment in Moa Technology, a plant genetics company using proprietary technology to generate new herbicide candidates, spun out of the University of Oxford.

23 July 2026 Oxford, UK – Moa Technology (“Moa”), an agricultural biotechnology company focused on discovering novel mode of action herbicides, announces a £22.2 million Series C financing round.

This new investment reflects the proven strength of Moa’s IP and the progress it has made to become the innovation partner of choice for the crop protection industry. In the last 24 months, Moa has formed R&D collaborations with four leading companies – Nufarm, Gowan, Belchim and Corteva Agriscience – to develop different novel solutions to help farmers protect their harvest from crop-killing weeds, and expects to continue to sign further commercial research partnerships.

In a major breakthrough for the industry, Moa’s proprietary technology platforms have already discovered over 80 novel mode of action areas, which work in completely different ways to control weeds and break resistance. After successful validation in the lab and glasshouse, Moa’s most advanced novel mode of action programmes are performing strongly to control some of the world’s toughest weeds in successive seasons of international field trials. In 2025, the company discovered a new category of products – Moa AmplifiersTM – which are not herbicidal on their own but have the potential to reduce the amount or concentration of herbicides required, supporting productivity and environmental stewardship.

The Series C funding will enable Moa to bring its three most advanced programmed significantly closer to commercialisation, to build its pipeline of early-stage novel mode of action herbicides to further develop the Moa Amplifiers programme. The new equity investment will be supplemented by upfront and milestone payments from current and future industry partners working with Moa.

Dr Virginia Corless, CEO of Moa Technology, said:

“This marks a major milestone for Moa Technology – a validation of the outstanding progress we have made not just in the laboratory, but also in striking commercial deals with leading industry partners around the world. We are particularly pleased that, through AIF in Europe and GainInnovate in Australia, the farming sector itself is closely connected to the next phase of Moa’s development, helping accelerate delivery of our solutions to the fields where that are so urgently needed.”

 

To find out more about Moa Technology, visit the Moa website or the Parkwalk portfolio page.

About Parkwalk

Parkwalk is the UK’s most active investor in university spinouts, backing transformative technologies developed by the country’s leading universities and research organisations. Parkwalk focuses on investing in companies addressing real-world challenges with IP-protected innovations across a broad range of sectors, including life sciences, artificial intelligence, quantum computing, advanced materials, genomics, cleantech, future mobility, medtech, and big data.

As the leading growth EIS fund manager, with £400 million in assets under management, Parkwalk has invested in over 200 companies through its Parkwalk Opportunities and Knowledge Intensive EIS Funds, as well as through enterprise and innovation funds managed for the Universities of Cambridge, Oxford, Bristol, and Imperial College. In 2025, Parkwalk introduced the Northern Universities Venture Fund, targeting opportunities emerging from the Universities of Leeds, Liverpool, Manchester, and Sheffield.

In partnership with our parent company, IP Group, we are dedicated to unlocking the potential of UK university research, supporting businesses throughout their journey from spinout to scale-up and from laboratory to market.

The products shown on this website will place your capital at risk and investors may not get back the full amount invested. Past performance may not be repeated and is not indicative of future results.

Parkwalk funds invest in smaller and unquoted companies which carry a higher risk than many other forms of investment. There is no guarantee that target returns will be achieved. There is no liquid market for shares in unquoted companies and there can be difficulties, in valuing and disposing of investments in such companies. Tax reliefs will depend on the investors’ individual circumstance and are subject to change.

Parkwalk does not provide investment or tax advice, and the information on this website should not be construed as such. Parkwalk recommends investors seek advice from a regulated financial adviser that specialises in EIS fund investments before making an investment decision. An investment into any of the funds managed by Parkwalk may only be made on the basis of the information set out in the Information Memorandum and Key Information Document.

The information on this website is directed at United Kingdom residents only. Please confirm you have read this warning and are happy to proceed.